Risk factors for prostate cancer and diagnosis and treatment for men with high-risk, aggressive disease

Long-Term Hormone Treatment After Radiation Helps Prostate Cancer Patients Live Longer Nov 1, 2005

Presence Of High-risk Prostate Cancer Can Be Predicted Without A Biopsy, New Study Says

While prostate cancer is a very common diagnosis, it is a deadly disease in relatively few men. One in 6 men will develop prostate cancer during his lifetime. However, of these, only one in 10 cases will be life-threatening. How to find those men at high risk?

"This is the prostate cancer paradox," said Mark Garzotto, M.D., lead study investigator. "The big question is how to decide which men have life-threatening cancer. These men need aggressive treatment. Men who don't have deadly cancer potentially may instead be closely monitored, sparing them the side effects of treatments." Garzotto thinks he knows a better way... Full story

Hormonal Treatment Improves Ten-Year Survival in High-Risk Prostate Cancer Patients Treated with Radiotherapy April 2005

Surgery for High Risk Patients at Mayo (results) April 2005

High blood testosterone levels associated with increased prostate cancer risk May 9 2004/ source: Johns Hopkins/ Men over 50 years of age with high blood levels of testosterone have an increased risk of prostate cancer, according to a study by researchers at Johns Hopkins and the National Institute on Aging. The finding throws some doubt on the safety of testosterone replacement therapy, the investigators say.

Gonorrhea, many sexual partners, linked to prostate cancer in men May 9 2004-- Men who have had gonorrhea are more likely to be diagnosed with prostate cancer, new research from the University of Michigan Health System finds.

Obesity linked to aggressive prostate cancer Dec 22 2003/ Source: Journal of Clinical Oncology; ASCO, Alexandria, VA/– Obese men with prostate cancer are more likely to have aggressive tumors and to experience cancer recurrence after surgery compared to men of normal weight or those who are overweight but not obese, according to two new studies.

Ki-67 Biomarker Predicts Outcome For Prostate Cancer Patients Treated with Androgen Deprivation plus Radiotherapy Oct. 23, 2003, Fox Chase Cancer Center. "Ki-67, along with PSA, Gleason score and stage, appears to be valuable in determining whether high-risk patients may be spared long-term androgen deprivation."

This page made and last edited by J. Strax, June 23, 2005.

Information on this website is not intended as medical advice nor to be taken as such. Consult qualified physicians specializing in the treatment of prostate cancer. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained on this website.

About Us | Site Archive | Content Policy/Disclaimer | Privacy Policy